Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: GlobeNewswire
NEWTON, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced dosing of the first patient in a randomized Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19. This global study is expected to enroll approximately 230 patients at clinical sites in the U.S., Europe, and Israel. Selinexor is an oral selective inhibitor of nuclear export (SINE) compound which blocks the cellular protein XPO1 which is involved in both the replication of SARS-CoV-2, the virus that causes COVID-19, and in the inflammatory response to the virus. The randomized, multi-center, placebo-controlled Phase 2 study (XPORT-CoV-1001/NCT04349098) of low dose selinexor is designed to assess the activity and safety of 20mg of selinexor given orally three times a week for two weeks. Patients tolerating therapy well and experiencing clinical benefit may be eligible to continue treatment for an additional two weeks at the
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Karyopharm Therapeutics Announces the Appointment of Chief Accounting OfficerPR Newswire
- Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
- Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and ExpositionPR Newswire
- Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]Yahoo! Finance
KPTI
Earnings
- 11/5/24 - Beat
KPTI
Analyst Actions
- 11/1/24 - HC Wainwright
KPTI
Sec Filings
- 11/20/24 - Form 8-K
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- KPTI's page on the SEC website